JP MORGAN/CALL/MODERNA/130/0.1/19.07.24 | Market Closed - Börse Stuttgart 14:31:46 2024-07-05 EDT | ||
| 0.11 EUR | -21.43% |
|
| Current month | -22.22% | ||
| 1 month | -92.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 0.11 | -21.43% |
| 24-07-04 | 0.14 | +42.86% |
| 24-07-03 | 0.098 | -24.62% |
| 24-07-02 | 0.13 | 0.00% |
| 24-07-01 | 0.13 | -27.78% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 02:31 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | J.P. Morgan |
| WKN | JL2KDQ |
| ISIN | DE000JL2KDQ0 |
| Date issued | 2023-04-28 |
| Strike | 130 $ |
| Maturity | 2024-07-19 (14 Days) |
| Parity | 10 : 1 |
| Emission price | 3.03 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.89 € |
|---|---|
| Lowest since issue | 0.089 € |
| Spread | 0.02 € |
| Spread % | 16.67% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
116
USD
Average target price
145.9
USD
Spread / Average Target
+25.79%
- Stock Market
- Warrants
- Warrant
